Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
2
40%
Ph phase_3
1
20%
Ph phase_4
2
40%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
N/ANon-phased studies
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Other(1)

Detailed Status

Recruiting2
Completed2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (20.0%)
Phase 42 (40.0%)
N/A2 (40.0%)

Trials by Status

recruiting240%
completed240%
unknown120%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_4

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation

NCT05955365
recruitingphase_3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
completednot_applicable

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

NCT03023020
unknownphase_4

Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT

NCT03112707
completednot_applicable

Study of AggreGuide A-100 (ADP) Assay

NCT03111420

Clinical Trials (5)

Showing 5 of 5 trials
NCT05955365Phase 4

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation

Recruiting
NCT02735707Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
NCT03023020Not Applicable

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen

Completed
NCT03112707Phase 4

Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT

Unknown
NCT03111420Not Applicable

Study of AggreGuide A-100 (ADP) Assay

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5